Lead Product(s) : Chidamide,Rituximab,Cyclophosphamide
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
NMPA Approves Chipscreen's Chidamide with R-CHOP for Diffuse Large B-Cell Lymphoma
Details : Chidamide (Epidaza®), an oral subtype-selective HDAC inhibitor, combined with R-CHOP, is approved by NMPA for treating DLBCL with positive MYC and BCL2 expression.
Brand Name : Epidaza
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 30, 2024
Lead Product(s) : Chidamide,Rituximab,Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : UB-421,Chidamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : UB-421 is an Fc-aglycosylated, non-T cell depleting and CD4-specific humanized IgG1 derived from the parent murine B4, which binds to discontinuous, conformational epitopes on the HIV-receptor complex, including CD4 (domain 1), and competitively blocks H...
Brand Name : UB-421
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 31, 2022
Lead Product(s) : UB-421,Chidamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Envafolimab,Chidamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Ascletis Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ASC22 (envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection such as hepatitis B virus (HBV) and HIV.
Brand Name : ASC22
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 14, 2022
Lead Product(s) : Envafolimab,Chidamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Ascletis Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Chidamide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Shenzhen Chipscreen Biosciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Data from the registration study of HBI-8000 has demonstrated clinically meaningful responses despite the advanced stage of disease and acceptable safety profile to address an important unmet medical need in this patient population.
Brand Name : HBI-8000
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 30, 2021
Lead Product(s) : Chidamide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Shenzhen Chipscreen Biosciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : UB-421,Chidamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : UB-421 is a strong entry inhibitor of HIV with proven ability to substitute for ART, and it may also enhance CD8 T cell cytotoxicity function and improve immune exhaustions .
Brand Name : UB-421
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 18, 2021
Lead Product(s) : UB-421,Chidamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Study confirms tolerability and significant anti-tumor activity of HBI-8000 in combination with nivolumab in checkpoint naive melanoma patients.
Brand Name : HBI-8000
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 09, 2020
Details : HBI-8000 is an epigenetic immunomodulator approved for the treatment of lymphoma and metastatic breast cancer in China. HBI-8000 targets class I histone deacetylase and suppresses the expression of the viral oncogene HTLV-I bZIP factor, NF-kB and the inf...
Brand Name : HBI-8000
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 28, 2020
LOOKING FOR A SUPPLIER?